“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
Iuliana Vaxman(Tel Aviv University), Morie A. Gertz(Medical University of South Carolina), Jithma P. Abeykoon(Mayo Clinic), Francis K. Buadi, Taimur Sher(Mayo Clinic in Florida), Nelson Leung(WinnMed), Robert A. Kyle(Mayo Clinic), Shaji Kumar(Mayo Clinic), Craig B. Reeder(Mayo Clinic in Arizona), Ronald S. Go(Mayo Clinic), Prashant Kapoor, Amie Fonder, Yi L. Hwa, Rahma Warsame, S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Mustaqeem Siddiqui(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Kristen McCullough(Mayo Clinic), Martha Q. Lacy(Mayo Clinic), Eli Muchtar(Mayo Clinic), Suzanne R. Hayman, Angela Dispenzieri(Mayo Clinic), Miriam Hobbs, David Dingli
Cited by 49
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k